文献速递胃肠动力与功能性疾病

Velusetrag加速胃轻瘫患者胃排空:一项多中心双盲随机安慰剂对照2期研究

Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-04-03

主要终点为第7天胃排空半衰期较基线降低≥20%的受试者比例,30 mg组显著高于安慰剂组(52% vs 5%,P=0.002),且耐受性总体良好。

要点

  • Velusetrag 30 mg显著提高胃排空半衰期降低≥20%的受试者比例(52% vs 5%,P=0.002)。
  • 三种剂量Velusetrag均使胃排空半衰期较安慰剂数值上缩短。
  • 糖尿病性与特发性胃轻瘫患者疗效相似,不良事件多为轻度胃肠道反应。

核心结论

  • Velusetrag可加速糖尿病性或特发性胃轻瘫患者的胃排空,且在该人群中总体耐受良好。

研究设计与样本

  • 受试者每日一次口服Velusetrag 5、15或30 mg或安慰剂,每个治疗期7天。
  • 胃排空采用[13C]-辛酸呼气试验测量。

主要发现

  • Velusetrag 30 mg组胃排空半衰期较基线降低≥20%的受试者比例为52%,安慰剂组为5%(P=0.002)。
  • 与安慰剂相比,Velusetrag三种剂量均使胃排空半衰期数值上缩短。
  • 糖尿病性与特发性胃轻瘫受试者之间的疗效相似。
  • 大多数治疗中出现的不良事件为轻度且与胃肠道转运加速相关。

关键数值与推荐

  • 主要终点为第7天胃排空半衰期较各治疗期基线降低≥20%的受试者比例。
  • Velusetrag 30 mg组与安慰剂组该比例分别为52%与5%,P=0.002。

临床怎么用

  • 对于糖尿病性或特发性胃轻瘫患者,Velusetrag 30 mg每日一次可能改善胃排空,但需关注轻度胃肠道不良反应。

局限性

  • 采用固定序列交叉设计,可能存在顺序效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastroparesis is a serious gastrointestinal (GI) condition characterised by delayed gastric emptying (GE). Velusetrag-a potent, selective, pan-gastrointestinal 5-hydroxytryptamine type 4 receptor agonist-is under investigation for treatment of GI motility disorders including gastroparesis. AIMS: To assess the efficacy and safety of velusetrag for accelerating GE in subjects with diabetic or idiopathic gastroparesis. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, three-period fixed-sequence crossover phase 2 study, subjects with diabetic or idiopathic gastroparesis received oral velusetrag (5, 15 or 30 mg) or placebo once daily for 7 days each. The primary outcome was proportion of subjects achieving ≥20% reduction in GE half-time (GE t1/2 ) from each treatment period baseline on day 7. Absolute and percent changes from baseline GE t1/2 were also assessed. GE was measured using a [13 C]-octanoate breath test. Safety was evaluated from treatment-emergent adverse events (TEAEs). RESULTS: Thirty-four subjects (67.6% female; mean age, 46.3 years; 52.9% with diabetic gastroparesis) were included. Treatment with velusetrag 30 mg significantly increased the proportion of subjects with ≥20% reduction from baseline GE t1/2 compared with placebo (52% vs 5%, P = 0.002), and GE t1/2 was numerically reduced following all three doses of velusetrag relative to placebo treatment. Efficacy was similar between subjects with diabetic and idiopathic gastroparesis. Velusetrag treatment was generally well tolerated; most TEAEs were mild and related to GI transit acceleration. CONCLUSIONS: Velusetrag accelerates GE in subjects with diabetic or idiopathic gastroparesis and is generally well tolerated in this population (Clinicaltrials.gov NCT01718938).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kuo B, Barnes CN, Nguyen DD, et al. Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Aliment Pharmacol Ther. 2021. PMID: 33811761. doi:10.1111/apt.16344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。